A multicomponent reaction involving ethylenediaminepalladium(II), 2-pyrimidinol derivatives (L) [L=2-pyrimidinol (a); 4-methyl-2-pyrimidinol (b); 4,6-dimethyl-2-pyrimidinol (c)] and 4,7-phenanthroline (4,7-phen) leads to the formation of heterotopic cyclic metallamacrocycles of the type [Pdn(en)n(mu-N,N'-L)m(mu-N,N'-4,7-phen)n-m](2n-m)+ [n=3, m=1 (3); n=4, m=2 (4); n=6, m=4 (5)]. These species can be obtained by different reaction pathways, including: (i) reaction of ethylenediaminepalladium(ii), L and 4,7-phen building blocks and (ii) reaction of the homotopic species [Pd4(en)4(mu-N,N'-L)4]4+ (1) and [Pd3(en)3(mu-N,N'-4,7-phen)3]6+ (2). The resulting heterotopic metallamacrocycles have been characterised by 1D and 2D 1H NMR spectroscopy. Additionally, species 3c and 4a have been studied by X-ray crystallography. The former one contains almost isosceles triangles of [Pd3(en)3(mu-N,N'-4,6-dimethyl-2-pyrimidinolate)(mu-N,N[prime or minute]-4,7-phen)2]5+ formulation, exhibiting a pinched-cone conformation. 4a contains a tetranuclear parallelogram [Pd4(en)4(mu-N,N'-2-pyrimidinolate)2(mu-N,N'-4,7-phenanthroline)2]6+, exhibiting a 1,3-alternate conformation. The host-guest properties of the here reported species have been studied, showing that they are able to interact with cationic as well as with anionic species.
No takes yet. Share an insight, caveat, or question.
Galindo et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: